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Significance of the Study
• Given the importance of drug-resistant Klebsiella pneumoniae and Escherichia coli strains in hospital-
acquired infections, the aim of this study was to determine the characteristics of ESBL, AmpC, and 
carbapenemase-producing isolates. Coexistence of AmpC, ESBL, and carbapenemase genes was ob-
served in some isolates. Implementing up-to-date strategies against such organisms is warranted.
DOI: 10.1159/000500311
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Abstract
Objectives: Drug resistance among gram-negative bacteria 
is a worldwide challenge. Due to the importance of drug-
resistant Klebsiella pneumoniae and Escherichia coli strains in 
hospital-acquired infections, we aimed to determine the 
phenotypic and genotypic characteristics of ESBL-, AmpC-, 
and carbapenemase-producing isolates obtained from hos-
pitalized patients in Tehran and Ilam (Iran). Materials and 
Methods: In total, 90 K. pneumoniae isolates and 65 E. coli 
isolates were collected from various infections. Phenotypic 
identification of bacterial isolates was performed using stan-
dard methods. Phenotypic screening of ESBL, AmpC, and 
carbapenemase enzymes was carried out. Detection of ESBL, 
AmpC, and carbapenemase genes was also performed by 
the PCR method. Results: Phenotypic detection tests showed 
that 36 (40%) K. pneumoniae and 23 (35.4%) E. coli isolates 
were ESBL producers. Moreover, 18 (20%) and 6 (9.2%) K. 
pneumoniae and E. coli isolates were AmpC producers, re-
spectively. Modified Hodge test results indicated that 39 
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(43.3%) K. pneumoniae and 18 (27.7%) E. coli isolates pro-
duced carbapenemase. Molecular tests showed that 40% of 
K. pneumoniae and 36.9% of E. coli isolates were ESBL posi-
tive. AmpC was detected in 24.4 and 13.8% of K. pneumoniae 
and E. coli isolates. Carbapenemase was detected in 34 
(37.8%) K. pneumoniae and 13 (20%) E. coli isolates. 
 Conclusion: In this study, 3 K. pneumoniae isolates simulta-
neously carried ESBL, AmpC, and carbapenemase genes. Up-
to-date strategies such as combination therapy or utilization 
of new antimicrobial agents might help to combat such 
drug-resistant organisms. © 2019 The Author(s)
Published by S. Karger AG, Basel
Introduction
Drug resistance in gram-negative bacteria is a world-
wide challenge [1]. Major resistance to gram-negative 
pathogens is related to Enterobacteriaceae, Acinetobacter 
baumannii, and Pseudomonas aeruginosa [2]. In the En-
terobacteriaceae family, Klebsiella pneumoniae and Esche-
richia coli have notable drug resistance. Also, they are the 
common cause of hospital- and community-acquired in-
fections [3, 4].
The wide distribution of extended-spectrum β-lac-
tamases (ESBLs) amongst Enterobacteriaceae has been 
attributed to the over- or misuse of these antibiotics [5]. 
ESBLs are able to hydrolyze various types of β-lactam an-
tibiotics, including cephalosporins and monobactams. 
Therefore, treating infections caused by ESBL-producing 
bacteria has become a complicated issue [5, 6]. Dissemi-
nation of hospital-acquired infections can be prevented 
via early detection of infections caused by such micro-
organisms [7].
Carbapenems have been considered as the treatment 
of choice for ESBL-producing gram-negative bacterial in-
fections. Carbapenemase-producing strains cause serious 
infections in hospitalized patients and are associated with 
mortality [8]; hence, the use of molecular techniques 
could be helpful in accurately diagnosing infections 
caused by ESBL- and carbapenemase-producing organ-
isms.
Drug-resistant strains of K. pneumoniae and E. coli in 
hospital-acquired infections are important [9]; thus, the 
aim of the present study was to determine the phenotyp-
ic and genotypic characterization of ESBL-, AmpC-, and 
carbapenemase-producing isolates of K. pneumoniae and 
E. coli obtained from hospital-associated infections in 
Tehran and Ilam (Iran).
Materials and Methods
Bacterial Strains
A total of 90 K. pneumoniae and 65 E. coli isolates were ob-
tained from various infections of hospitalized patients between 
April 2016 and March 2017 in Tehran and Ilam. Phenotypic and 
biochemical identification of bacterial isolates was performed ac-
cording to standard methods [10].
Phenotypic Screening of ESBL, AmpC, and Carbapenemase 
Enzymes
All isolates were initially screened for ESBL production by a 
combined disk method according to the guidelines of the Clinical 
Laboratory Standards Institute (CLSI) [11]. Briefly, susceptibility 
to cefotaxime (30 μg), cefotaxime/clavulanate (30/10 μg), ceftazi-
dime (30 μg), and ceftazidime/clavulanate (30/10 μg) (Mast Co., 
UK) was determined on Müller-Hinton agar (Merck Co, Germa-
ny). ESBL-producing strains were recognized by an at least 5-mm 
increase in zone diameter around cefotaxime/clavulanate and 
ceftazidime/clavulanate disks in comparison with disks without 
clavulanic acid. E. coli ATCC 35218 was used as the control strain 
[11].
Cefoxitin disks (30 μg) were used to screen AmpC-producing 
isolates according to CLSI recommendations [11]. A cefoxitin-
cloxacillin double-disk synergy test was carried out to confirm 
AmpC production, as previously described [12].
The modified Hodge test (MHT) was performed to screen car-
bapenemase-producing isolates [11]. K. pneumoniae ATCC BAA-
1705 and BAA-1706 were used as MHT-positive and -negative 
controls [11].
Detection of ESBL-, AmpC-, and Carbapenemase-Related 
Genes 
Polymerase chain reaction was performed using specific primers 
to detect genes encoding ESBLs (blaTEM, blaSHV, blaCTX-M, and 
blaPER), AmpC (blaACC, blaDHA, blaEBC, blaFOX, blaMOX, and 
blaCIT), and carbapenemase (blaIMP, blaVIM, blaNDM, blaKPC, and 
blaOXA-48-like), as previously described [13–17]. The products were 
separated by electrophoresis in 1% agarose gel with 1× TBE (Tris/
borate/EDTA) buffer, stained with safe stain load dye (CinnaGen 
Co., Tehran, Iran) and visualized under ultraviolet illumination.
Statistical Analysis
The distribution of resistance genes among resistant and sus-
ceptible isolates was calculated using χ2 and Fisher’s exact tests for 
each gene. p values ≤0.05 were considered to be statistically sig-
nificant.
Results
Phenotypic ESBL detection tests indicated that 36 
(40%) K. pneumoniae isolates and 23 (35.4%) E. coli iso-
lates were ESBL producers. Moreover, 32 (35.5%) K. 
pneumoniae and 19 (29.2%) E. coli isolates were AmpC 
positive, while phenotypic confirmatory tests showed 
that 18 (20%) and 6 (9.2%) K. pneumoniae and E. coli 
strains, respectively, were AmpC producers; 39 (43.3%) 
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K. pneumoniae and 18 (27.7%) E. coli strains produced 
carbapenemase.
Molecular methods showed that 36 (40%) K. pneu-
moniae isolates harbored at least 1 of the ESBL-related 
genes. Distribution of these genes among K. pneumoniae 
strains were blaTEM 23.3%, blaSHV 21.1%, and blaCTX-M 
11.1%. Presence of blaTEM and blaSHV genes in ESBL-pro-
ducing K. pneumoniae isolates was statistically significant 
(p < 0.05). In addition, 24 (36.9%) E. coli isolates were 
ESBL positive. The prevalence of blaTEM and blaSHV genes 
was 16.9%, and blaCTX-M was observed in 21.5% of iso-
lates. The blaPER gene was not detected in any of the 
strains. The blaCTX-M gene was more prevalent in E. coli 
isolates which were ESBL producers (Table 1).
AmpC-associated genes were detected amongst 22 
(24.4%) K. pneumoniae isolates. blaDHA, blaCIT, and blaEBC 
were found among 16.6, 5.5, and 13.3% of K. pneumoniae 
strains, respectively. blaDHA prevalence in AmpC-posi-
tive K. pneumoniae isolates was statistically significant 
(p < 0.05). Furthermore, 9 (13.8%) of the E. coli isolates 
carried AmpC genes, and the distribution percentages of 
blaDHA, blaCIT, and blaEBC were 6.1, 3, and 4.6%, respec-
tively. All the strains were negative for blaACC, blaFOX, and 
blaMOX (Table 2).
Carbapenemase-related genes were detected in 34 
(37.8%) K. pneumoniae isolates. The prevalence rates of 
these genes were blaVIM 33.3%, blaOXA-48-like 14.4%, and 
blaIMP 1.1%. Thirteen (20%) E. coli isolates were carba-
penemase positive. blaVIM and blaOXA-48-like were observed 
in 12.3 and 20% of isolates, respectively. No blaIMP gene 
was detected in E. coli strains. blaNDM and blaKPC genes 
were not found in any of the bacterial isolates. blaVIM  
and blaOXA-48-like gene distribution was significantly dif-
ferent (p < 0.05) among K. pneumoniae and E. coli isolates 
(Table 3).
Table 1. Distribution of ESBL-associated genes among K. pneumoniae and E. coli isolates
Isolate ESBL blaTEM blaSHV blaCTX-M blaPER
phenotypic genotypic
K. pneumoniae 36 (40) 36 (40) 21 (23.3)* 19 (21.1)* 10 (11.1) 0
E. coli 23 (35.4) 24 (36.9) 11 (16.9) 11 (16.9) 14 (21.5)* 0
Values are presented as n (%). * p < 0.05. 
Table 2. Distribution of AmpC-related genes among K. pneumoniae and E. coli isolates
Isolate AmpC positive blaACC blaDHA blaEBC blaFOX blaMOX blaCIT
screening test confirmatory test genotypic
K. pneumoniae 32 (35.5) 18 (20) 22 (24.4) 0 15 (16.6)* 12 (13.3) 0 0 5 (5.5)
E. coli 19 (29.2) 6 (9.2) 9 (13.8) 0 4 (6.1) 3 (4.6) 0 0 2 (3)
Values are presented as n (%). * p < 0.05.
Table 3. Carbapenem resistance patterns among K. pneumoniae and E. coli isolates
Isolate Carbapenemase producer blaIMP blaVIM blaNDM blaKPC blaOXA-48-like
MHT genotypic
K. pneumoniae 39 (43.3) 34 (37.8) 1 (1.1) 30 (33.3)* 0 0 13 (14.4)
E. coli 18 (27.7) 13 (20) 0 8 (12.3) 0 0 13 (20)*
Values are presented as n (%). MHT, modified Hodge test. * p < 0.05. 
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Discussion
In the present study, the prevalence of ESBL-, AmpC-, 
and carbapenemase-associated genes were investigated 
by phenotypic and genotypic methods in clinical isolates 
of K. pneumoniae and E. coli. According to the pheno-
typic results, the prevalence of ESBL-producing K. pneu-
moniae and E. coli was notable. The genotypic method 
confirmed the phenotypic method results, except for 1 E. 
coli strain. Although this isolate harbored 1 ESBL-related 
gene, it did not show phenotypic resistance. Similarly, un-
expressed ESBL genes in antibiotic-susceptible isolates 
were previously reported [18]. Horizontal gene transfer 
to other bacteria is possible via such strains [18].
Notable frequencies of ESBL-producing K. pneumo-
niae and E. coli strains were reported in Iran [19, 20]. It 
seems that the prevalence of ESBL-producing gram-neg-
ative bacteria is increasing in the country [20].
In the present study, 8 K. pneumoniae isolates carried 
2 ESBL genes, and 3 isolates harbored 3 ESBL genes si-
multaneously. Moreover, the simultaneous presence of 
2 and 3 ESBL genes was observed in 6 and 3 strains of E. 
coli, respectively. The copresence of ESBL genes among 
clinical E. coli isolates was previously stated [21].
In the present study, AmpC screening and confir-
matory phenotypic tests produced different results. 
Similar to a previous study, a high rate of false-negative 
results was reported by phenotypic detection methods 
for AmpC [13]. In our study, AmpC-producing K. 
pneumoniae strains were higher than in a previous re-
port from Iran [22]. However, a notable frequency of 
AmpC-producing K. pneumoniae isolates (43%) was 
reported among burnt patients [13]. Dissemination of 
AmpC β-lactamases between near half of clinical gram-
negative bacilli has been reported [13, 23, 24]. In the 
present study, 6 AmpC-producing K. pneumoniae iso-
lates carried blaDHA and blaEBC simultaneously, and 
copresence of blaDHA, blaEBC, and blaCIT was observed 
in 2 isolates. Recently, the coexistence of AmpC 
β-lactamase genes in K. pneumoniae was reported for 
the first time [13]. To eradicate AmpC-producing bac-
teria, carbapenems can be used as primary agents, but 
AmpC β-lactamases might increase the MIC values of 
carbapenems and confer resistance to the carbapenem 
family [13, 25].
A frequent gene among carbapenemase-producing K. 
pneumoniae was blaVIM, but only 1 harbored the blaIMP 
gene. Similarly, in a previous study, the blaVIM gene was 
more frequent than the blaIMP gene [26]. The blaKPC and 
blaNDM genes were not detected in any of the investigated 
strains, while the presence of blaKPC was notable in K. 
pneumoniae isolates in Iran [27]. Also, in a study by Hos-
seinzadeh et al. [28], > 10% of the isolates carried the 
blaNDM-1 gene.
Among carbapenemase-producing K. pneumoniae, 
8 (23.5%) isolates simultaneously harbored blaVIM and 
blaOXA-48-like genes, and the copresence of blaVIM, 
blaOXA-48-like, and blaIMP genes was detected in only 1 iso-
late (2.9%). Among carbapenemase-producing E. coli iso-
lates, 8 (61.5%) carried blaVIM and blaOXA-48-like genes 
simultaneously. The blaOXA-48-like gene was detected 
among all of them.
Our results indicated that some resistance genes were 
present amongst the resistant strains, which was statisti-
cally significant (p < 0.05). These appear to be the most 
frequent ESBL-, AmpC-, and carbapenemase-related 
genes in our region (Tables 1–3). Coexistence of ESBL, 
AmpC, and metallo-β-lactamases was reported amongst 
A. baumannii strains in 2013 [29]. Pokhrel et al. [30] 
showed the copresence of ESBLs and carbapenemase in 
clinical E. coli isolates in Nepal.
The current study shows that 2 K. pneumoniae isolates 
simultaneously carried 2 ESBL (blaCTX-M, blaTEM / blaCTX-M, 
blaSHV), 2 AmpC (blaDHA and blaEBC), and 2 carbapene-
mase genes (blaVIM and blaOXA-48-like). Moreover, coexis-
tence of 3 ESBL (blaCTX-M, blaTEM, and blaSHV), 1 AmpC 
(blaDHA), and 3 carbapenemase genes (blaVIM, blaOXA-48-like, 
and blaIMP) was seen in 1 of the studied isolates.
Conclusion
For the first time, we reported the occurrences of 
ESBL, AmpC, and carbapenemase genes in K. pneumoni-
ae strains in Iran. In the present study, 2 isolates simul-
taneously carried 2 ESBL genes, 2 AmpC, and 2 car-
bapenemase genes. Moreover, coexistence of 3 ESBL, 1 
AmpC, and 3 carbapenemase genes was observed in 1 K. 
pneumoniae isolate. Therefore, K. pneumoniae can be 
considered as a major pathogen and important hazard 
for public health. Up-to-date treatment with combina-
tion therapy and/or new antimicrobial agents, for exam-
ple, might be helpful against such drug-resistant organ-
isms.
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